The Effect of Early Treatment with Intravenous Magnesium Sulfate on the Incidence of Cardiac Comorbidities in Hospitalized Stroke Patients

Table 2

Dichotomized demographic and clinical characteristics of patients who achieved and did not achieve blood serum magnesium study target within 72 hours (3.8 mEg/L).

	Patients with serum Mg ≥3.8 mEg/L ()	Patients with serum Mg <3.8 mEg/L ()	value
Age (mean, SD)	73.5 (13.1)	68.3 (13.3)	<0.0001
Sex female (, percent)	134 (52.8)	338 (38.8)	<0.0001
Diagnosis, (%)
Acute cerebral ischemia	178 (70.1)	631 (72.4)	0.13
0.13 intracranial hemorrhage	205 (23.5)	72 (28.3)
Stroke mimic	4 (1.6)	35 (4.0)
Race, (%)
White	203 (79.9)	651 (74.7)	0.06
Black/African American	22 (8.7)	135 (15.5)
Asian	27 (10.6)	75 (8.6)
Other	2 (0.8)	10 (1.2)
Ethnicity–Hispanic, (%)	65 (25.6)	205 (23.5)	0.27
Medical history
Hypertension, (%)	202 (79.5)	675 (77.5)	0.55
Diabetes, (%)	51 (20.1)	199 (22.8)	0.39
Hyperlipidemia, (%)	111 (43.7)	422 (48.5)	0.10
Atrial fibrillation, (%)	63 (24.8)	191 (21.9)	0.35
CAD, (%)	61 (24.0)	184 (21.1)	0.34
MI, (%)	31 (12.2)	94 (10.8)	0.57
CABG, (%)	6 (2.4)	24 (2.8)	0.82
Prior stroke/TIA, (%)	23 (8.3)	65 (7.5)	0.69
Tobacco use, (%)	41 (16.1)	158 (18.1)	0.51
Any alcohol use, (%)	87 (34.4)	356 (40.9)	0.06
Time intervals (mins), median (IQR)
Onset to paramedic evaluation	16 (8-32)	16 (8-36)	0.73
Onset to ED arrival	58 (46-77)	58 (46-80)	0.82
Severity scores
Prehospital GCS, median (IQR)	15 (14-15)	15 (14-15)	0.90
Prehospital LAMS, median (IQR)	4 (3-5)	4 (3-5)	0.48
Serum magnesium level mean (SD)	4.7 (0.9)	2.3 (0.7)	<0.0001
Patients with CAEs, (%)	47 (18.5)	112 (12.8)	0.03
Number of CAEs, (%)
0	207 (81.5)	760 (87.2)	0.09
1	40 (15.7)	96 (11.0)
2	7 (2.8)	14 (1.6)
3	0 (0.0)	2 (0.2)